ACL injuries are some of the most common knee injuries in sports, and they are front of mind for many active people in Honolulu, from surfers and paddlers to weekend soccer and basketball players. Because recovery is long and surgery is a big decision, regenerative options such as platelet-rich plasma (PRP) and stem cells receive a lot of attention and a lot of marketing. This article sorts through what the newest 2025 and 2026 studies actually show for ACL reconstruction, ligament healing, and the choice between surgery and nonsurgical care.
33
randomized trials in the updated 2026 meta-analysis of PRP in ACL reconstruction
1,082
patients pooled across 18 trials in the 2025 PRP knee-stability meta-analysis
0
completed human meta-analyses of stem-cell-augmented ACL reconstruction as of 2026
The ACL, or anterior cruciate ligament, is one of the main stabilizing ligaments in the knee, and tears happen in sports with sudden stops, cuts, and landings: soccer, basketball, volleyball, and even surfing pileups and ocean paddling. Recovery from an ACL tear is measured in months, the decision to have surgery is genuinely hard, and reinjury is common. That combination makes it exactly the kind of injury that sends people searching for anything that might heal faster or avoid the scalpel. In 2025 and 2026, researchers published a wave of new evidence on whether PRP and stem cells actually deliver, and the honest answer is more nuanced than most marketing suggests.
A March 2026 update to a systematic review and meta-analysis, now covering 33 randomized controlled trials of PRP in ACL reconstruction, found that PRP's effect on postoperative pain depended on where the injection was given and how long after surgery it was measured. An April 2026 meta-analysis of randomized trials reported significant differences favoring PRP on pain scores at 6 and 12 months and on Lysholm knee scores. A July 2025 meta-analysis of 18 trials and 1,082 patients found PRP modestly improved one measure of knee stability (KT-1000, by about 0.57 millimeters) but showed no significant benefit for pain, overall knee scores, or tunnel widening. Read together, these analyses describe a modest, time-dependent advantage for some measures, not a dramatic transformation.
“A 2026 systematic review of 33 randomized trials found PRP's effect on pain after ACL reconstruction depended on injection site and follow-up time, and even the more positive analyses describe a modest, time-dependent advantage rather than a dramatic one.”
Then came a prospective randomized trial published in Scientific Reports in July 2026, which found that PRP did not improve pain, function, or graft maturation after ACL reconstruction. Its authors noted that earlier meta-analyses consistently show no clinically meaningful early pain reduction, and their trial adds a high-quality result pointing the same direction. Read side by side with the meta-analyses above, the fair conclusion is this: PRP after ACL surgery might modestly help some people in some ways, and it clearly does not help everyone. How a clinic presents these mixed data matters more than the marketing around the injection.
“A prospective randomized trial published in Scientific Reports in July 2026 found PRP did not improve pain, function, or graft maturation after ACL reconstruction, consistent with earlier meta-analyses showing no clinically meaningful early pain reduction.”
For people trying to avoid surgery altogether, the most-discussed 2025 study is a two-year randomized crossover trial from BMC Musculoskeletal Disorders comparing percutaneous bone marrow concentrate plus platelet products against exercise therapy for ACL tears treated without surgery. The authors reported better outcomes in the cell and platelet group, but it remains a single trial with a crossover design, and experts are careful to point out that successful nonsurgical ACL programs, when appropriate, depend heavily on structured rehabilitation. The evidence is genuinely promising and genuinely early, which is not the same thing as proven.
A 2026 systematic review of stem-cell-augmented ACL reconstruction found heavily heterogeneous results: some studies reported gains in graft maturation, pain, and imaging outcomes, while others found no benefit, and there is still no completed human meta-analysis on the topic. For other knee ligaments the evidence is thinner still. A 2025 case series of ultrasound-guided PRP for deep medial collateral ligament (MCL) injuries reported short-term benefit and urged further study. Preclinical work continues, including a 2026 protocol for a systematic review of tendon-bone healing after ACL reconstruction in animal models, but that sits far from a recommendation for a patient.
Here is the practical takeaway. If you have torn your ACL, the most important decision is the surgical-versus-nonsurgical one, made with imaging, a careful exam, and a surgeon or sports medicine provider you trust. PRP and cell therapy sit on the edges of that decision: they may modestly support pain relief, stability measures, or graft maturation; they do not replace rehabilitation; and their evidence in a completely torn ACL is mixed. A reputable clinic will tell you exactly what the data do and do not support for your specific situation, and it will walk away from a treatment that is not supported. That honesty is the whole point.
A note from the clinic
Ligament injuries deserve an honest, unhurried conversation, not a sales pitch. At Aloha Stem Cell in Honolulu we will review your imaging, explain what the 2025 and 2026 evidence does and does not support for PRP and cell therapy, and help you connect with the right surgeon or sports medicine provider when that is the honest answer. Call (808) 593-2525 or book a consultation.
Our team is happy to listen to your story, answer your questions, and help you decide whether a consultation makes sense. There is no pressure and no obligation.
Keep reading
The FDA now lists Regenecyte, a cord blood stem cell product, among approved cellular therapies. It is a real milestone for blood stem cell transplant patients, and it is not a treatment for joint pain. Here is what the approval is, what it is not, and why it matters when you read stem cell news.
In September 2026 the FDA granted Fast Track status to an experimental cell therapy for ALS, and in August researchers presented new Phase 1/2 data on a stem cell therapy for Parkinson's. Both are real advances and both remain investigational. Here is the honest read.
A stem cell-derived islet therapy restored insulin production in early trials, with 10 of 12 patients insulin-independent at one year. Here is what the 2025-2026 results show, what the FDA has and has not done, and what it means for people with diabetes.
Book a consultation
Pick a time that works for you and our team will confirm your consultation. Questions first? Call us anytime at (808) 593-2525.